Pharma BD Deal Intelligence
A wholly owned subsidiary of Hansoh Pharmaceutical Group entered a collaboration development agreement with AilsynBio to apply AilsynBio's AI platform to the discovery of novel oral cyclic peptide drug candidates. Hansoh may select targets, acquire the intellectual property rights for the corresponding programs and lead subsequent development. AilsynBio is eligible for aggregate payments of up to RMB 317 million plus single-digit royalties on potential net sales of products developed under the programs.
← Browse all deals · How we score deals
More: 2026 deals · Hansoh Pharmaceutical Group Co. Ltd. deals